Meta‐analysis: the outcome of anti‐viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
Open Access
- 23 July 2008
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 28 (4), 397-404
- https://doi.org/10.1111/j.1365-2036.2008.03763.x
Abstract
Background Anti‐viral therapy seems more successful in HCV genotype 2 than genotype 3‐infected patients. Aim To report sustained virological response (SVR) rates for HCV‐2 and HCV‐3 infection. Methods Meta‐analyses were carried out on SVR data on 2275 patients treated for 24 weeks in eight individual trials and on 968 patients with rapid virological response (RVR) treated for 12–16 weeks or 24 weeks in four studies. Results After 24 weeks of therapy, SVR rates were 74% and 68%, respectively, for HCV‐2 and HCV‐3 genotype patients. Among high viraemics, SVR rate in HCV‐2 infection (75%) differed from the 58% value in HCV‐3 infection. Among low viraemic patients, respective rates were 79% and 75%. In RVR patients treated for 12–16 or 24 weeks, SVR rates in HCV‐2 infection were 83% and 84%, respectively, and in HCV‐3 infection 84% and 86%. In patients without RVR treated for 24 weeks, SVR was higher in HCV‐2, with a 17.8% weighted difference. Conclusions Twenty‐four weeks of therapy should remain standard duration for HCV‐2 and low viraemic HCV‐3 patients. In RVR patients, HCV‐3 patients respond to short‐treatment as well as HCV‐2 patients, irrespective of basal viraemia. Patients without RVR may need longer treatment than the recommended 24 weeks.Keywords
This publication has 16 references indexed in Scilit:
- Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological responseHepatology, 2007
- Short-term treatment duration for HCV-2 and HCV-3 infected patientsDigestive and Liver Disease, 2006
- Comparison of two PEG‐interferon alpha‐2b doses (1.0 or 1.5 μg/kg) combined with ribavirin in interferon‐naïve patients with chronic hepatitis C and up to moderate fibrosisJournal of Viral Hepatitis, 2006
- Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis CGastroenterology, 2005
- Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3New England Journal of Medicine, 2005
- Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirinJournal of Hepatology, 2005
- Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot studyHepatology, 2004
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Meta-analytic Tools for Medical Decision Making: A Practical GuideMedical Decision Making, 1995